Olaparib Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 100 mg, 150 mg
Reference Brands: Lynparza® (US & EU)
Category:
Oncology Cancer Care
Olaparib Tablets (brand: Lynparza®) are oral PARP inhibitors for ovarian, breast, pancreatic, and prostate cancers, especially in BRCA-mutated cases. Available in 100 mg and 150 mg, and approved in the US and EU, Olaparib offers a reliable, GMP-compliant oncology solution for global B2B pharmaceutical distribution.
Olaparib is available in Tablet
and strengths such as 100 mg, 150 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Olaparib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Olaparib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Olaparib Tablets, sold under the brand name Lynparza®, are oral PARP inhibitors used in treating advanced ovarian, breast, pancreatic, and prostate cancers, especially in patients with BRCA mutations. Olaparib interferes with cancer cell DNA repair, enhancing cell death in tumors with deficient repair mechanisms. Available in 100 mg and 150 mg strengths, these tablets are approved in both the US and EU and manufactured under GMP-certified facilities. As a breakthrough targeted therapy, Olaparib is a valuable option for oncology-focused pharmaceutical partners seeking high-quality, globally compliant formulations for B2B supply in regulated markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing